Woburn, MA, November 09, 2005—BioTrove is pleased to announce the expansion of its relationship with Sirtris Pharmaceuticals. As part of the ongoing relationship, BioTrove will use its proprietary RapidFire™ Lead Discovery service for assay development and high throughput screening on an undisclosed number of Sirtris targets. RapidFire™ Lead Discovery uses high throughput mass spectrometry to perform label-free assays using native biological substrates enabling the screening of intractable targets.

"The expansion of our relationship with Sirtris provides further validation of the value of RapidFire™ Lead Discovery. Our expanding customer base continues to find new leads and information on valuable targets when compared to classical HTS methods," said Alan Carter, Vice President of Business Development and Field Operations.

About BioTrove, Inc.
BioTrove, Inc. is a biotechnology company focused on advancing life science and drug discovery research by leveraging revolutionary micro- and nano-scale technologies. BioTrove has two core platforms: OpenArray™ Applications based on Through-Hole technology, a broadly applicable nano-liter fluidics technology platform for massively parallel and low-volume analysis of genetic, genomic, proteomic, biochemical and cellular samples and RapidFire™ Lead Discovery, an assay development and high throughput screening service that unlocks the value of intractable drug targets. For more information contact, please visit www.biotrove.com.

For more information contact:

Alan Carter
BioTrove, Inc.
acarter@biotrove.com
(781) 721-3648

Can "Jon" Özbal, Ph.D.
BioTrove, Inc.
781-721-3605
cozbal@biotrove.com